Effect of SAMe-TT2R2 score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin

被引:4
作者
Elewa, Hazem [1 ]
Qurishi, Iqrah [2 ]
Abouelhassan, Rawan [2 ]
Abou Safrah, Salam [2 ]
Alhamoud, Eman [3 ]
Bader, Loulia [2 ]
机构
[1] Qatar Univ, Coll Pharm, Clin Pharm & Practice Sect, QU Hlth, POB 2713, Doha, Qatar
[2] Qatar Univ, Coll Pharm, QU Hlth, Doha, Qatar
[3] Alwakra Hosp, Doha, Qatar
关键词
Same-TT2R2; Pharmacogenetics; Warfarin; Direct oral anticoagulants; Time in therapeutic range; ATRIAL-FIBRILLATION; VENOUS THROMBOEMBOLISM; ORAL ANTICOAGULANTS; NATIONAL TRENDS; DABIGATRAN; RIVAROXABAN; GENOTYPE; PREDICTS; VALIDATION; PREVENTION;
D O I
10.1007/s11239-020-02102-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is no strong evidence on pharmacogenetics role on the quality of INR control after the initiation phase and on the maintenance of stable INR on the long term as measured by the time in therapeutic range (TTR). The benefit of a score such as SAMe-TT2R2 is that it can preemptively guide clinicians on whether to start the patient on warfarin or direct oral anticoagulant. To determine the association between genetic variants in CYP2C9, VKORC1, and CYP4F2 and TTR. To validate SAMe-TT2R2 score predictive ability on the quality of anticoagulation in Qatari patients. This is an observational nested case-control study that was conducted on a cohort of Qatari patients treated with warfarin with previously identified genotype for the CYP2C9, VKORC1, and CYP2F4. The sample size of this cohort was 148 patients. Mean TTR was 62.7 +/- 21%. TTR was not significantly different among carriers of the CYP2C9*2 &*3, VKORC1(-1639G>A) or CYP4F2*3 compared to their non-carriers alleles. None of the factors in the SAMe-TT2R2 score had a significant effect on the TTR except for the female gender where TTR was significantly lower in females (n = 89) compared to males (n = 59) (59.6 +/- 21% vs. 67.2 +/- 20%, p = 0.03). Furthermore, patients with SAMe-TT2R2 score of zero had significantly better TTR compared to those with higher scores (76.5 +/- 17% vs. 61.8 +/- 21%, p = 0.04). Logistic regression analysis showed that high SAMe-TT2R2 score was the only statistically significant predicting factor of poor INR control (odds ratio (OR) 5.7, 95% confidence interval (CI) 1.1-28.3, p = 0.034). Genetic variants have no contribution to the quality of INR control. SAMe-TT2R2 score was predictive for the poor quality of anticoagulation in a cohort of Qatari patients.
引用
收藏
页码:659 / 666
页数:8
相关论文
共 50 条
  • [31] Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment
    Gorzelak-Pabis, Paulina
    Zyzak, Sandra
    Krewko, Lukasz
    Broncel, Marlena
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (7-8): : 494 - 501
  • [32] The SAMe–TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia
    Nijole Bernaitis
    Tony Badrick
    Shailendra Anoopkumar-Dukie
    Journal of Thrombosis and Thrombolysis, 2020, 50 : 614 - 618
  • [33] SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation
    Krittayaphong, Rungroj
    Winijkul, Arjbordin
    Pirapatdit, Atthasit
    Chiewvit, Pollakrit
    Komoltri, Chulalak
    Boonyapisit, Warangkna
    Arunsiriwattana, Suchart
    Bunyapipat, Tanita
    Apiyasawat, Sirin
    Rattanasumawong, Kasem
    Yindeengam, Ahthit
    SINGAPORE MEDICAL JOURNAL, 2020, 61 (12) : 641 - 646
  • [34] Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE
    Barco, Stefano
    Granziera, Serena
    Coppens, Michiel
    Douxfils, Jonathan
    Nijkeuter, Mathilde
    Riva, Nicoletta
    Vanassche, Thomas
    Zhang, George
    Lin, Min
    Kamphuisen, Pieter W.
    Cohen, Alexander T.
    Beyer-Westendorf, Jan
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (04) : 675 - 684
  • [35] The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population
    Bernaitis, Nijole
    Ching, Chi Keong
    Chen, Liping
    Hon, Jin Shing
    Teo, Siew Chong
    Davey, Andrew K.
    Anoopkumar-Dukie, Shailendra
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (01) : 64 - 69
  • [36] Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
    Ntaios, George
    Huisman, Menno, V
    Diener, Hans-Christoph
    Halperin, Jonathan L.
    Teutsch, Christine
    Marler, Sabrina
    Gurusamy, Venkatesh K.
    Thompson, Milla
    Lip, Gregory Y. H.
    Olshansky, Brian
    HELLENIC JOURNAL OF CARDIOLOGY, 2021, 62 (02) : 152 - 157
  • [37] Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain
    Lobos-Bejarano, Jose M.
    Barrios, Vivencio
    Polo-Garcia, Jose
    Escobar, Carlos
    Vargas-Ortega, Diego
    Marin-Montanes, Nuria
    Prieto-Valiente, Luis
    Fuentes, Sonia
    Angel Prieto, Miguel
    Garcia-Ortiz, Luis
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (07) : 1201 - 1207
  • [38] The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists
    Fauchier, Laurent
    Angoulvant, Denis
    Lip, Gregory Y. H.
    EUROPACE, 2015, 17 (05): : 671 - 673
  • [39] Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis
    van Miert, Jasper H. A.
    Bos, Sarah
    Veeger, Nic J. G. M.
    Meijer, Karina
    PLOS ONE, 2018, 13 (03):
  • [40] Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT2R2 score
    Methavigul, Komsing
    Yindeengam, Ahthit
    Krittayaphong, Rungroj
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)